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Efficacy of Dendritic Cells Matured Early with OK-432 
(Picibanil®), Prostaglandin E2, and Interferon-α as a Vaccine for a 
Hormone Refractory Prostate Cancer Cell Line
Dendritic cells (DCs) are potent antigen-presenting cells. OK432 (Picibanil
®) was introduced 
as a potent stimulator of DC maturation in combination with prostaglandin-E2 and 
interferon-α. We compared the efficacy of a DC-prostate cancer vaccine using early-
mature DCs stimulated with OK432, PGE2 and INF-α (OPA) with that of vaccines using 
other methods. On days 3 or 7 of DC culture, TNF-α (T), TNF-α and LPS (TL) or OPA were 
employed as maturation stimulators. DU145 cells subjected to heat stress were hybridized 
with mature DCs using polyethyleneglycol. T cells were sensitized by the hybrids, and their 
proliferative and cytokine secretion activities and cytotoxicity were measured. The yields of 
early-mature DCs were higher, compared to yields at the conventional maturation time 
(P<0.05). In the early maturation setting, the mean fusion ratios, calculated from the 
fraction of dual-positive cells, were 13.3%, 18.6%, and 39.9%, respectively (P=0.051) in the 
T only, TL, and OPA-treated groups. The function of cytotoxic T cells, which were sensitized 
with the hybrids containing DCs matured early with OPA, was superior to that using other 
methods. The antitumor effects of DC-DU145 hybrids generated with DCs subjected to 
early maturation with the OPA may be superior to that of the hybrids using conventional 
maturation methods. 
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INTRODUCTION
Cancer cells are self-altering cell populations that often do not 
derive an appropriate response from the immune system. Lack 
of tumor antigen presentation may lead to a deficit in the capa-
bility of the host immune system to destroy immunogenic tu-
mor cells (1). Dendritic cells (DCs) are the most potent antigen-
presenting cells (APCs) that play major roles in innate and ac-
quired immunity. Tumor antigen-loaded DCs have been suc-
cessfully applied as therapeutic vaccines to induce specific im-
munity against cancer. Mature DCs are better at inducing anti-
cancer immune responses in vaccinated patients than imma-
ture cells. 
  Various techniques have been developed for improving the 
yield of mature DCs and enhancing their immune responses 
against cancer. Among these, a streptococcal preparation, OK432 
(Picibanil
®), increases the efficiency of DC maturation and in-
duction of antigen-specific cytotoxic T cells in colorectal cancer 
cell lines (2). Interestingly, ‘rapidly generated’ fully mature DCs 
stimulated by a combination of OK432, low-dose prostanoids, 
and interferon-α (OPA) act as more potent immune enhancers 
than those stimulated via other methods (3). Here, we investi-
gate the efficacy of early matured DCs treated with OPA as a fu-
sion vaccine for the treatment of hormone-refractory prostate 
cancer.
MATERIALS AND METHODS
Generation of DCs from peripheral blood monocytes 
Peripheral blood was drawn from healthy volunteers with in-
formed consent, after the approval of the institutional review 
board (2007-12-159). Briefly, peripheral blood monocytes 
(PBMCs) were isolated from the buffy coat layer of blood by 
Lymphoprep
® density-gradient separation (Axis-shield PoC AS, 
Oslo, Norway) after centrifugation at 1,800 r.p.m. Next, cells were 
incubated in culture flasks at 37˚C for 2-3 hr in AIM-V (GIBCO) 
medium. Aliquots of harvested cells were cryopreserved in 90% 
heat-inactivated fetal bovine serum (FBS) (GIBCO, Carlsbad, 
CA, USA) plus 10% dimethylsulfoxide (DMSO) (Sigma-Aldrich 
Corp. St. Louis, MO, USA). The remaining adherent cells were Yoo C, et al.  •  Efficacy of Dendritic Cells as a Vaccine for a Hormone Refractory Prostate Cancer Cell Line 
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cultured in AIM-V medium supplemented with interleukin-4 
(IL-4) (40 ng/mL) and GM-CSF (50 ng/mL) (R&D Systems, Inc., 
Minneapolis, MN, USA). Fresh medium was added up to half of 
the volume daily. Three sets of DC stimulatory agents were pre-
pared, specifically, TNF-α only (20 mg/mL) (T only set), TNF-α 
(20 mg/mL) plus lipopolysaccharides (LPS) (1 μg/mL) (TL set), 
and OK432 (0.1 KE/mL) (Chugai Pharm. Co. Ltd., Taipei, Tai-
wan), prostaglandin E2 (50 ng/mL), and interferon-α (500 IU/
mL) (OPA set). For conventional maturation of DCs, stimulato-
ry agents were added on day 7 of culture. For early maturation, 
the three sets of agents were added on day 3 of culture. Using 
the six maturation methods combined the three sets of stimu-
lating agents with two time-points (early and conventional), the 
efficacies of the mature dendritic cells were compared (Fig. 1).
Phenotype analysis and yield of mature DCs
Cells were incubated with FITC-conjugated antibodies against 
MHC class II (HLA-DR), costimulatory molecules (CD80 and 
CD86), and DC maturation markers (CD83, CCR7). PKH26, a 
prostate cancer marker, in a red fluorescent cell linker kit, was 
used to validate cancer cells. Using these markers, cell pheno-
types were analyzed with FACS (Fluorescent activated cell sort-
er-FACSCalibur
TM; BD Immunocytometry Systems, San Hose, 
CA). The yield of mature DCs obtained with each of the six meth-
ods was compared via FACS analysis detecting CD86, a marker 
for mature dendritic cells. 
Tumor cell lines 
A hormone refractory human prostate cancer cell line, DU145, 
was purchased from the American Type Culture Collection 
(ATCC, Manassas, VA). The cell line was maintained in RPMI1640 
medium, and used for fusion vaccines and cytotoxicity assays.
DC/tumor hybridization 
DU145 cells were subjected to heat shock (42˚C) for 2 hr, followed 
by recovery for 24 hr at 37˚C (4). After the pretreatment, cells 
were mixed with mature DCs prepared using the six maturation 
methods in a 50 mL tube at a ratio of 1:2. For hybridization, poly-
ethylene glycol (PEG) (PEG1500, Roche Diagnostics, Mannheim, 
Germany) was pre-warmed to 37˚C, and added directly to the 
mixed cell pellet. Following hybridization, 25 mL of 37˚C AIM-V 
medium was added slowly to cells. The DC-DU145 hybrids 
were characterized by FACS with the red fluorescent cell linker 
kit, PKH26. DCs were characterized by directly labeled CD86-
FITC (Serotec, Oxford, UK). For FACS analysis, DC-DU145 hy-
brids were washed with PBS, and incubated with antibodies for 
30 min at room temperature. Each fusion ratio of the hybrids in 
the six combination sets was analyzed and compared. 
Generation of tumor-specific T cells 
T cells were thawed and treated with IL-7 (20 ng/mL) and IL-12 
(100 pg/mL) (R&D Systems Inc.). After overnight incubation, 
naïve T cells (responder cell) were stimulated with hybridized 
and non-hybridized DCs (stimulator cell) at the ratio of 10:1, re-
spectively. Responder cells were cultured in X-vivo 15 medium 
supplemented with IL-7 (20 ng/mL), IL-12 (100 pg/mL) and 2% 
autologous plasma for 3 days. On day 4 of co-culture, IL-2 (20 
IU/mL) (R&D Systems, Inc.) was added, and cytotoxicity against 
tumor cells analyzed. 
T cell proliferation assay
Primary allogeneic mixed leukocyte reaction (MLR) was per-
formed with hybridized and non-hybridized cells. Cells were co-
cultured with 10
5 allogeneic T cells/well in 96-well plates for 3 
days. BrdU (1 μCi) was added to each well at 15-20 hr before har-
vest. Incorporation of BrdU (Roche, Penzberg, Germany) was 
measured colorimetrically. 
Cytokine production assays 
Supernatant fractions from PEG-treated and untreated DCs and 
DU145 tumor cell cultures were collected at 24-48 hr after hy-
bridization, and analyzed for IL-12 secretion by DC-DU145 hy-
brids using ELISA (Mabtech AB, Stockholm, Sweden). ELISA 
was performed according to the manufacturer’s instructions, 
and quantitated using a VERSAmax microplate reader (Molec-
ular Devices Corp., Sunnyvale, CA, USA). Interferon-gamma 
(INF-γ) secreted by tumor-specific CD8+ CTL cells were also 
analyzed using ELISA (Mabtech AB).
Cytotoxicity assays 
T cells stimulated with DC-DU145 hybrids were co-cultured 
with DU145 in 96-well plates for 24 hr at 37°C. The CytoTox-ONE 
assay
® (Promega, Medison, WI, USA) provided a measurement 
of lactate dehydrogenase (LDH) released from cells with dam-
aged membrane. All steps were performed according to the man-
ufacturer’s instructions. Briefly, after washing cells with assay 
medium (AIM-V), plates were centrifuged, and supernatant 
fractions were transferred to a flat-bottomed ELISA plate. The 
Various maturation methods of dendritic cells
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Fig. 1. Study design of six maturation method combinations, specifically, early matu­
ration with TNF­α only (20 mg/mL), TNF­α (20 mg/mL) plus lipopolysaccharides (LPS) 
(1 µg/mL), and a cocktail of OK432 (0.1 KE/mL), PGE2 (50 ng/mL), and interferon­α 
(500 IU/mL) on day 3, compared with conventional maturation with the above agents 
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LDH detection mixture was added to each well and incubated 
in the dark for 10 min at room temperature. Stop solution was 
added, and the fluorescent signal (560EX/590EM) measured with 
a Fluorescence plate reader. 
Statistical analysis
The non-parametric Mann-Whitney test was used for the com-
parison of mean values between the two independent variables, 
and Kruskal-Wallis test for three or more independent vari-
ables. 
RESULTS
Phenotypes and yields of mature DCs 
The mean number of harvested DCs was 8×10
6 cells per 50 mL 
of PBMC. HLA-DR, CD80, CD83, and CD86 were expressed at 
higher levels in mature DCs than immature cells. The DU145 cell 
line did not contain these molecules, and expressed PKH26 (data 
not shown). The yield of mature DCs was high at the early mat-
uration time-point, irrespective of the type of stimulator (P=0.012). 
Moreover, yields tended to increase in the order of T only, TL, 
and OPA, in both early and conventional maturation settings. 
Specifically, the mean yield of mature DCs was 43.1% with the 
T only set, 47.8% with the TL set, and 58.7% with the OPA set in 
the early maturation setting, and 17.2%, 21.9%, and 27.4%, re-
spectively, in the conventional setting (Table 1). Data from FACS 
analyses revealed a right shift in the figure in the same order, 
confirming this finding. FACS data for CD86 are presented in 
Fig. 2. Overall, the highest yield of early mature DCs was obtain-
ed with OPA. 
Fusion of DCs and DU145
Fusion was performed with 2×10
6 DCs and 1×10
6 DU145 cells 
(2:1) stimulated with PEG solution. Hybridized cells were identi-
fied via dual positivity for PKH26-PI and CD86-FITC in FACS 
analysis (Fig. 3). In a conventional maturation setting, fusion 
ratios were comparable among cells stimulated with different 
types of maturation agents. However, under early maturation 
conditions, the fusion ratio of DU145 and DCs matured with the 
OPA set was the highest (28.7-60.8%), while that of DU145 and 
DCs matured with the T only set was the lowest (10.7-17.7%). 
The mean fusion ratios, calculated from the fraction of dual-posi-
tive cells, were 13.3%, 18.6%, and 39.9%, respectively (P=0.051) in 
the T only, TL, and OPA-treated groups. However, in the con-
ventional maturation setting, fusion ratios were not different 
among the groups (9.9%, 11.2% and 13.1%, respectively). Cells 
generated at the early maturation time-point (3 days) addition-
ally displayed superior efficacy to those obtained at the conven-
tional time (7 days) in terms of fusion ratio (P=0.01) (Fig. 4).
Table 1. Yields of mature dendritic cells with different combinations of maturation 
times and stimulators: the result of 5 blood samples (T only, 20 mg/mL TNF­α; TL, 
20 mg/mL TNF­α+1 µg/mL LPS; OPA, 0.1 KE/mL OK432+50 ng/mL PGE2+50 ng/
mL INF­α)
T only (%)
† TL (%)
† OPA (%)
† P value
Early maturation 43.1±44.7 47.8±40.8 58.7±34.3
0.012* Conventional maturation 17.2±23.0 21.9±32.9 27.4±31.8
*Significance of early and conventional maturation; 
†P>0.05 for maturation stimulating 
agents.
DU145
Fig. 2. Phenotyping of immature and mature dendritic cells (DC), and DU145 cell lines analyzed by flow cytometry using various surface molecules.
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Function of DC-DU145 hybrids 
In view of the superiority of early maturation, the conventional 
maturation method was excluded in subsequent functional 
studies. The functions of hybrids were evaluated by measuring 
the level of IL-12, a cytokine secreted by mature DCs that is the 
most powerful known stimulator for inducing innate T cells to 
CD8+ T cells. Among the stimulatory agents, the OPA set was the 
most effective in promoting IL-12 secretion from the hybrids. 
Compared to the T only set, the OPA set was significantly more 
efficacious (P=0.021) but the TL set was not (P=0.083) (Fig. 5).
Enhanced T cell activation by DC-DU145 hybrids
DC-DU145 hybrids enhanced the proliferation of CD8+ T cells 
by sensitizing them to tumor antigens upon co-culture. Tumor-
sensitized CD8+ cytotoxic T cells (CTL) produced a cytokine, 
IFN-γ. Similar to the IL-12 secretion function of DC-DU145 hy-
brids, T cell proliferation by OPA-treated DC-DU145 hybrids 
and IFN-γ secretion by sensitized CTLs were significantly supe-
rior to data obtained with hybrids of DCs matured using other 
methods (Figs. 6, 7).
Cytotoxicity of CTLs with different stimulations
In general, the cytotoxicity results were similar to those obtained 
from previous functional analyses. The cytotoxicity of CTLs sen-
sitized with hybrids containing OPA-treated DCs was stronger 
than that of CTLs sensitized with hybrids containing T only-
treated or TL-treated DCs (Fig. 8). The mean percentage of tumor 
lyses was 29.6% in the T only set, 42.8% in the TL set, and 62.9% 
in the OPA set. Compared to the T only set, the OPA set was sig-
nificantly more efficacious (P=0.049) but the TL set was not.
DISCUSSION
Anti-cancer vaccines are a suggested treatment modality for 
advanced prostate cancer, and have been investigated in sever-
al clinical trials. The generation of high numbers of mature DCs 
is essential to obtain a potent anti-cancer vaccine, which is cur-
rently a challenging and unresolved issue (5). Various method-
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ological improvement, including a range of DC maturation stim-
ulators, maturation times, techniques of tumor antigen loading 
to DCs, and treatment of tumor cells before tumor antigen load-
ing, have been explored to achieve this aim. While the evidence 
obtained to date is controversial (6, 7), the efficacy of the fusion 
procedure is superior to that of the tumor lysate-stimulating 
method (8, 9).
  In the present study, we adopted recent findings on anti-tu-
mor fusion vaccines for prostate cancer. Lundqvist and col-
leagues (10) suggested that an allogeneic tumor-dendritic cell 
fusion vaccine against prostate cancer is a potent stimulator 
of the broad prostate tumor-specific response. They employed 
TNF-α and IL-4 as maturation stimulating agents and conven-
tional maturation times, and reported a hybrid yield of 10-25%. 
Our data confirm the superiority of the OPA combination as a 
DC maturation stimulator, and demonstrate that early matura-
tion of DCs promotes the efficacy of antigen presentation to a 
greater extent than conventional 7-day maturation. Moreover, 
the overall yield of DC-DU145 hybrids obtained was 15-60%. 
  The feasibility of DC maturation as early as 2-day culture was 
reported by Tanaka and co-workers (11). They showed that ‘rap-
id DCs’ are equally as potent as ‘7-day conventional mature DCs’ 
in inducing specific CTLs in vitro. Sakakibara and colleagues (3) 
reported similar results with colorectal cancer cell lines. Their 
data showed that quickly generated mature DCs were superior 
to those obtained with conventional 7-day maturation in terms 
of antigen-presenting ability. It was assumed that the shorter 
culture period gave rise to larger numbers of DCs, and quicker 
generation of DCs was beneficial for the maintenance of cell 
quality. The apoptosis rate of DCs increased from 10% to 25% 
over one week of culture (12). Our results support previous data 
showing that the yield of mature DCs is consistently and signifi-
cantly higher in early cultures than the conventional 7-day time-
period, irrespective of other conditions. 
  Upon culture with GM-CSF and IL-4, only immature DCs are 
harvested, which would induce immune tolerance in vivo (5). 
Maturation of DCs in vitro is inducible by inflammatory stimuli, 
such as TNF-α, IL-1β, LPS, unmethylated DNA containing CpG 
motifs, CD40 ligation, and contact sensitizers (13-16). Conven-
tionally, TNF-α with or without LPS is employed for stimulating 
DC maturation. The LPS ligand combines with Toll-like recep-
tor 4 (TLR4), a surface molecule of DCs, which, in turn, initiates 
intracellular signal transduction to the nucleus. Consequently, 
nuclear factor κB and Jun/Fos are activated at the nuclear level, 
and a series of gene expression steps mediate maturation of DC 
(17). Eventually, Th2 differentiation is induced by TNF-α and 
LPS. OK432, a lyophilized preparation of the Su strain of Strep-
tococcus pyogenes inactivated with penicillin G, is a non-specif-
ic immunomodulator. The compound acts in combination with 
TLR4 to affect various immune functions, not only enhancement 
of cytotoxic cells, lymphocytes, macrophages, and NK cells, but 
also stimulation of cytokine secretion, such as interferons, 
TNF-α, and IL-2 (5). Several recent evidence show that OK432 
is more effective than LPS in promoting the maturation of DCs 
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(5, 18, 19). Our data also were similar to the results of previous 
studies. We estimated that the optimal concentration of LPS for 
maturation of DCs is 1 μg/mL. The maturation yield of DCs was 
decreased at a LPS dosage over 1 μg/mL, possibly resulting from 
cytotoxicity of LPS.
  Conventionally, prior to hybridization, cancer cells are apop-
tosed via ionizing radiation ranging between 15 and 150 Gy to 
enhance fusion efficacy (10, 20). Instead of irradiation, we ap-
plied heat stress to tumor cells, which had a synergic effect on 
the induction of antigen-specific CTL with TLR-stimulated DCs, 
as suggested by Koido et al. (21). However, we have not com-
pared the efficacy of heat-stress techniques with irradiation of 
DU145 cell lines as preparative procedures for hybridization in 
this analysis. 
  In most in vitro anti-cancer vaccine studies, the more effica-
cious DC maturation methods showed superior result in cyto-
toxicity against cancer cells, and functions of antigen-loaded 
DCs and sensitized CTLs. In view of the significant superiority 
of the early maturation procedure in the DC and DC-DU145 
hybrid analyses, conventional maturation was excluded in sub-
sequent functional studies. Among the DC maturation agents, 
OPA was the strongest immune modulator in cytokine secretion 
of the hybrids, T cell sensitization with cancer antigens, and T 
cell proliferation. While OPA induced the highest percentage of 
cytotoxicity, its superiority was not statistically significant in 
comparison to the other compound sets due to the small num-
ber of tests performed (only two samples). Additional studies 
are ongoing to acquire more data on cytotoxicity. 
  The main limitation of this study is that tumor specificity for 
DU145 in the cytotoxicity analysis was not clearly validated. To 
confirm this, the cytotoxicity of CTLs sensitized with DC-DU145 
hybrids should be compared with that of the CTLs sensitized 
with the DC hybrids with cancer cell line originated from other 
organs. Another drawback was the significant diversity in cell 
quality of PBMCs among the donors. We abandoned data show-
ing poor viability at the beginning of the study. Despite of this 
initial serum quality control, significant inter-personal varia-
tions were consistently observed throughout the analysis. To 
improve data quality, the initial amount of peripheral blood 
obtained from the donors may be increased from 50 mL to about 
500 mL or higher, or PBMCs collected from volunteers injected 
with GM-CSF. Additional in vivo studies are required to apply 
the results to the clinical setting. 
  Enhancing the number and activity of the effecter cells using 
the presented methods in this study, the clinical results of can-
cer vaccine treatment for hormone refractory prostate cancer 
may be improved. 
  In conclusion, the antitumor effects of DC-DU145 hybrids 
generated with DCs subjected to early maturation with the OPA 
may be superior to the effects of those matured using conven-
tional methods. 
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